Study: Monoclonal antibodies hold promise for childhood cancer

10/4/2009 | Reuters

British scientists found that three monoclonal antibodies, anti-41BB, anti-CD40 and anti-CTLA4, proved effective in killing 40% to 60% of neuroblastoma in laboratory tests. The antibodies attack cancer cells by recognizing and activating the immune system's response. "It is hoped that these antibodies can be used to boost or 'super charge' the body's immune system to help it fight cancer," the researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT